The Capital Network represents the new age of analytical
research coverage. At Capital Network, we are dedicated to helping organisations manage investor
perception within the market and empowering investors with tier 1 research, providing access to high
quality companies that they were unaware of or previously did not have access to. Companies are
assigned an industry-leading analyst, whom will have extensive sector knowledge, numerous
accreditations and a track record of delivering success. Each client's industry-leader provides
dynamic analytical coverage including: investment research, video insights and social media alerts.
This digital content is then distributed online via various platforms enabling access to thousands
of institutional investors, including: investment banks, conventional fund managers, hedge funds,
wealth managers, and trusts. The analysis also reaches a vast network of PCBs, family offices,
thousands of private investors and headlines on numerous impactful financial platforms.
Judges Scientific (JDG.LON) stands out as a unique player of consolidating scientific instruments market. With its extensive merger history over the past 10 years and combined expertise of highly experienced management teams at both the parent and subsidiaries, the long-term growth outlook for the company appears intact...
Lionel Therond, Capital Network's Oil & Gas analyst gives his view on the news that Green Dragon Gas Ltd's (LON:GDG) development plan for the Qinshui Basin Chengzhuang Cooperative CBM Block (GCZ) has been approved by the Consultation Center of China National Petroleum Corporation (CNPC).
Quadrise Fuels International Plc (QFI.LON) (“Quadrise”) is a London (AIM) listed company engaged in the manufacture and marketing of a low viscosity oil-in-water emulsion fuel (MSAR®) for use as a synthetic, low-cost and environmentally friendlier substitute for conventional heavy fuel oil, in power generation and marine...
On April 3rd Avacta (AVCT.LON) released the results of a pre-clinical study showing that Affimers have an immunogenicity profile comparable to widely used biotech drugs. This leaves Avacta (AVCT.LON) on track to move their immuno-oncology therapeutic Affimer into the clinic by 2019.
Capital Network's Healthcare Analyst Riccardo Lowi gives his view on Redx Pharma Plc (LON:REDX).
''The reason it's a particularly exciting time for the company is because they're moving their two lead candidates into the clinical stage, it's the first time they're moving a drug candidate into human trials'',...
Charles Taylor (CTR.LON) is a global provider of professional services to clients across the insurance sector. In addition to providing the traditional services of insurance management, loss adjusting and claims services, it is at the forefront of exciting new developments in “insurtech”. Charles Taylor...
Harvest Minerals (HMI.LON) is a London AIM listed fertiliser project developer, with assets located in Brazil. Following a recent downwards move in the share price (perhaps as a result of profit taking), the cash flow metrics for Harvest Minerals appear highly compelling.
VinaCapital Opportunity Fund (VOF.LON) is a closed end fund domiciled in Guernsey, and provides exposure to the attractive growth market of Vietnam. We believe it is a very efficient way to gain exposure, and the quality of the fund is underpinned by its strong management team which has international experience, but...
Oxford BioMedica, a UK-based, clinical stage biotech company, is a global leader in the exciting and rapidly advancing field of gene and cell therapy. They have their own portfolio of pre-clinical and clinical-stage product candidates and also have licensed technology and provide revenue-generating services to third...
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.